(Verbatim from the application): Hypertrophic heart disease is an important clinical problem producing substantial morbidity, mortality and health care expense. The peptide endothelin-1 (ET-1) is one of the signals for the development of cardiac hypertrophy. In order to examine the likely autocrine/paracrine role of endogenous cardiomyocyte endothelin in hypertrophy we have chosen a genetic approach to eliminate the endothelin-1 gene from the hearts of transgenic mice. However, a traditional knockout of the endothelin gene produces pharyngeal hypoplasia, which leads to suffocation shortly after birth, and prevents evaluation of the physiological effects of the mutation in adult mice. We have therefore created a cardiac specific knockout of the endothelin gene to test our central hypothesis that ET-1 acts as a paracrine facilitator of diverse hypertrophic stimuli. We have three specific aims: 1) To determine the hypertrophic and contractile response of the ET-1 deficient heart in specific models of hypertrophy. 2) To identify the genes that are transcriptionally regulated by ET-1 signaling in the setting of these models of hypertrophy. 3) To determine the effect of ET-1 ablation on the response of the CNA, CamK4 and MAPK dependent hypertrophic pathways. Methods will include: 1) Cardiac specific deletion of ET-1 by breeding of mice containing Cre recombinase under the regulation of the cardiac specific alpha-myosin heavy chain promoter and a lox-bracketed endothelin-1 gene. 2) Stimulation of hypertrophy with exogenous thyroid, isoproterenol and angiotensin infusion. 3) Measurement of hypertrophic response by: a. Expression of genes involved in myocardiocyte growth (Northern and RT-PCE techniques), b. a broad evaluation of transcriptional response (microarray analysis), and c. anatomic remodeling and ventricular performance (MRI imaging). 4) Enzyme assays of the activity of CNA, CamK4 and MAPKs in hearts of ET-1 deleted and wild-type mice subjected to hypertrophic stimuli.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL064041-03
Application #
6537732
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Fakunding, John
Project Start
2000-07-01
Project End
2005-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
3
Fiscal Year
2002
Total Cost
$273,000
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Schorlemmer, Anita; Matter, Michelle L; Shohet, Ralph V (2008) Cardioprotective signaling by endothelin. Trends Cardiovasc Med 18:233-9
Zhao, Xiao-Song; Pan, Wentong; Bekeredjian, Raffi et al. (2006) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114:830-7
Shohet, Ralph V; Kisanuki, Yaz Y; Zhao, Xiao-Song et al. (2004) Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci U S A 101:2088-93
Bekeredjian, Raffi; Chen, Shuyuan; Pan, Wentong et al. (2004) Effects of ultrasound-targeted microbubble destruction on cardiac gene expression. Ultrasound Med Biol 30:539-43
Zhao, Xiao-Song; Gallardo, Teresa D; Lin, Ling et al. (2002) Transcriptional mapping and genomic analysis of the cardiac atria and ventricles. Physiol Genomics 12:53-60